Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
6.35
-0.11 (-1.70%)
May 15, 2026, 10:13 AM EDT - Market open
Company Description
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 489 |
| CEO | Michael Raab |
Contact Details
Address: 400 Fifth Avenue, Suite 210 Waltham, Massachusetts 02451 United States | |
| Phone | 510 745 1700 |
| Website | ardelyx.com |
Stock Details
| Ticker Symbol | ARDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001437402 |
| CUSIP Number | 039697107 |
| ISIN Number | US0396971071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Raab | President, Chief Executive Officer and Director |
| Eric Duane Foster | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | SCHEDULE 13G | Filing |
| Apr 30, 2026 | 10-Q | Quarterly Report |
| Apr 30, 2026 | 8-K | Current Report |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Feb 24, 2026 | 144 | Filing |
| Feb 23, 2026 | 144/A | Filing |
| Feb 20, 2026 | 144 | Filing |